Name | N-(Phenylsulfonyl)-6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]nicotinamide |
---|---|
Synonyms |
N-(Phenylsulfonyl)-6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]nicotinamide
3-Pyridinecarboxamide, N-(phenylsulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]- |
Description | Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor and Ivacaftor in cystic fibrosis research[1]. |
---|---|
Related Catalog | |
In Vitro | Bamocaftor is a CFTR corrector designed to restore F508del-CFTR protein function[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C28H32F3N5O4S |
Molecular Weight | 591.64 |
Exact Mass | 591.212708 |
LogP | 5.71 |
Index of Refraction | 1.622 |